FLT3 and acute myeloid leukemia: One of the most common AML mutations is the FMS-like tyrosine kinase 3 (FLT3) receptor gene with FLT3 internal tandem duplications (FLT3-ITD) and point mutations in the tyrosine kinase domain (FLT3-TKD), which occurs in 18.9% to 24.9% [2–4] and 5.0% to 6.2% [4, 5] of newly diagnosed adult patients with AML, respectively.